Wissenschaftliche Arbeiten

Prof. Dr. Nedim Turan

110 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Quelle: OpenAlex

  3. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  5. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  7. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  8. Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020553 PMID 41598493 Frei zugänglicher VolltextQuelle: OpenAlex

  9. Clinical Outcomes of Stage IS Non-seminomatous Germ Cell Testicular Tumors: Single-Center Experience

    Istanbul Medical Journal, 2026

    DOI 10.4274/imj.galenos.2026.62829 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041671 PMID 41753358 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62061004 PMID 42356017 Frei zugänglicher VolltextQuelle: OpenAlex

  12. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Prognostic Factors and Survival in Thymoma and Thymic Carcinoma: A Retrospective Cohort Study

    Cerrahpasa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26089 Frei zugänglicher VolltextQuelle: OpenAlex

  14. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Frei zugänglicher VolltextQuelle: OpenAlex

  15. Correlación entre los parámetros metabólicos derivados de la PET/TC con [18F]FDG y la expresión de PD-L1 en pacientes con cáncer de pulmón no microcítico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2026

    DOI 10.1016/j.remn.2025.500258 Quelle: OpenAlex

  16. EP943 - ECE_3402 - Vitamin D status and metabolic parameters in patients with concomitant parathyroid adenoma and breast cancer: a retrospective case–control pilot study

    European Journal of Endocrinology, 2026

    DOI 10.1093/ejendo/lvag096.1232 Frei zugänglicher VolltextQuelle: OpenAlex

  17. Association Between Metastatic Patterns and Overall Survival in Metastatic Gastric Cancer: A Single-Centre Real-World Study

    The European Research Journal, 2026

    DOI 10.18621/eurj.1310 Frei zugänglicher VolltextQuelle: ORCID

  18. First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15155997 PMID 42590101 Frei zugänglicher VolltextQuelle: ORCID

  19. Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study

    Northern Clinics of Istanbul, 2026

    DOI 10.14744/nci.2026.65391 PMID 42158883 Frei zugänglicher VolltextQuelle: ORCID

  20. Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

    Oncology Letters, 2026

    DOI 10.3892/ol.2026.15750 PMID 42491228 Frei zugänglicher VolltextQuelle: ORCID

  21. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

    Cancer Control, 2026

    DOI 10.1177/10732748261432273 PMID 41779425 Frei zugänglicher VolltextQuelle: ORCID

  22. First Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From Turkey

    2026

    DOI 10.20944/preprints202607.0722.v1 Frei zugänglicher VolltextQuelle: ORCID

  23. Clinicopathologic and Treatment-Related Determinants of Pathologic Complete Response and Survival Outcomes in Triple-Negative Breast Cancer: A Real-World Cohort Study

    Biomedicines, 2026

    DOI 10.3390/biomedicines14112482 Frei zugänglicher VolltextQuelle: OpenAlex

  24. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61061075 PMID 40572762 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25042 Frei zugänglicher VolltextQuelle: OpenAlex

  26. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  27. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  28. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  29. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

    Journal of Personalized Medicine, 2025

    DOI 10.3390/jpm16010008 PMID 41590501 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

    Medicina, 2025

    DOI 10.3390/medicina61101813 PMID 41155800 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  31. Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm15010247 PMID 41517497 Frei zugänglicher VolltextQuelle: OpenAlex

  32. Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

    Breast Cancer Research and Treatment, 2025

    DOI 10.1007/s10549-025-07694-7 PMID 40214840 2 Zitationen (Europe PMC) Quelle: OpenAlex

  33. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  34. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  35. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

    Pharmaceuticals, 2025

    DOI 10.3390/ph18060931 PMID 40573326 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  36. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32090503 PMID 41002573 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Frei zugänglicher VolltextQuelle: OpenAlex

  38. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

    Cancers, 2025

    DOI 10.3390/cancers17071076 PMID 40227569 Frei zugänglicher VolltextQuelle: OpenAlex

  39. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

    Healthcare, 2025

    DOI 10.3390/healthcare13151810 PMID 40805843 Frei zugänglicher VolltextQuelle: OpenAlex

  40. Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25030 Frei zugänglicher VolltextQuelle: OpenAlex

  41. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20501 Frei zugänglicher VolltextQuelle: OpenAlex

  42. Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61010154 PMID 39859134 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  43. Efficacy of Palbociclib and Ribociclib in Second-line Treatment of Metastatic Hormone Receptor-positive Breast Cancer: A Single-center Experience

    Journal of Oncological Science, 2025

    DOI 10.37047/jos.galenos.2025.2025-4-2 Frei zugänglicher VolltextQuelle: ORCID

  44. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

    Breast Cancer Research and Treatment, 2024

    DOI 10.1007/s10549-024-07456-x PMID 39123071 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  45. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  46. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  47. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  48. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 Zitationen (Europe PMC) Quelle: OpenAlex

  49. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  50. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex